GLP-1 Market
LLY $1169.60 ▼ -1.6% NVO $38.18 ▼ -0.2% PFE $27.82 ▼ -0.6% VKTX $27.73 ▼ -2.8% KLRA $10.00 ▼ -5.0% GPCR $25.67 ▼ -3.8% RHHBY $53.29 ▼ -1.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Venetoclax

Company
Columbia University
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
173 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

173 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 9, 2026

Find a Clinical Trial Near Me

See recruiting studies for Venetoclax and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT00501826

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 160 participants Est. completion 2028-10-31 1 site Stand-alone
    Other conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT02115295

    Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 508 participants Est. completion 2030-05-31 1 site Stand-alone
    Other conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT02781883

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

    Not yet reported Bio-Path Holdings, Inc. 108 participants Est. completion 2028-12 9 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT03013998

    Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    Not yet reported, Not yet reported Beat AML, LLC 3000 participants Est. completion 2032-12 31 sites Stand-alone
    Other conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT03214562

    Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 116 participants Est. completion 2027-09-30 1 site Stand-alone
    Other conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT03223610

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 155 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03586609

    Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 145 participants Est. completion 2027-04-30 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT03680677

    Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

    Abramson Cancer Center at Penn Medicine 20 participants Est. completion 2027-11 1 site
    Other conditions: Leukemia, Acute, MDS
    View official trial listing →
  • Recruiting NCT NCT03826992

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

    Not yet reported Children's Hospital Medical Center, Cincinnati 21 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Recruiting NCT NCT03850574

    Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported Aptose Biosciences Inc. 240 participants Est. completion 2027-04 34 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT03868722

    Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

    Not yet reported, Not yet reported Copenhagen University Hospital, Rigshospitalet 212 participants Est. completion 2030-07-31 7 sites Stand-alone
    Other conditions: CLL
    View official trial listing →
  • Recruiting NCT NCT03874052

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Jennifer Saultz 51 participants Est. completion 2027-12-31 3 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT04140487

    Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 97 participants Est. completion 2028-09-01 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04169737

    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 168 participants Est. completion 2028-07-09 1 site Stand-alone
    Other conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04216524

    Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04256317

    A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Not yet reported, Not yet reported Taiho Oncology, Inc. 316 participants Est. completion 2028-11-01 73 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT04269902

    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    Not yet reported National Cancer Institute (NCI) 247 participants Est. completion 2028-10-01 632 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04581512

    Study to Evaluate the Safety and Tolerability of EP0042

    Not yet reported, Not yet reported Ellipses Pharma 70 participants Est. completion 2027-12 6 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT04588922

    Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

    Not yet reported, Not yet reported Sellas Life Sciences Group 160 participants Est. completion 2027-12-31 32 sites Stand-alone
    Other conditions: Hematologic Malignancies
    View official trial listing →
  • Recruiting NCT NCT04628026

    Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

    Not yet reported University of Ulm 650 participants Est. completion 2032-02 91 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT04708054

    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 324 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Recruiting NCT NCT04777916

    Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

    Acute Leukemia French Association 5000 participants Est. completion 2046-04-01 30 sites
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT04840602

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    Not yet reported National Cancer Institute (NCI) 92 participants Est. completion 2028-03-31 145 sites Stand-alone
    Other conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Recruiting NCT NCT04855695

    Avo In R/R And Previously Untreated MCL

    Not yet reported, Not yet reported Austin I Kim 72 participants Est. completion 2027-12-31 3 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma, Refractory Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04905810

    Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

    Not yet reported Brian Jonas 20 participants Est. completion 2025-12-01 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT04941716

    Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

    Not yet reported Fred Hutchinson Cancer Center 20 participants Est. completion 2031-08-10 1 site Stand-alone
    Other conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04988555

    A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    Not yet reported, Not yet reported Sumitomo Pharma America, Inc. 606 participants Est. completion 2027-12-31 104 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT05010122

    ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2028-01-30 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05074355

    Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

    Not yet reported University Health Network, Toronto 40 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT05099471

    Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

    Not yet reported Christian Buske 80 participants Est. completion 2033-03 14 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, Treatment Naive
    View official trial listing →
  • Recruiting NCT NCT05168930

    Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

    Not yet reported Dana-Farber Cancer Institute 45 participants Est. completion 2028-10-28 4 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Recruiting NCT NCT05183035

    Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

    Not yet reported PedAL BCU, LLC 130 participants Est. completion 2031-04 90 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05183854

    Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

    Not yet reported University of Utah 61 participants Est. completion 2028-06 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05211570

    AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported AB Science 78 participants Est. completion 2026-12 10 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05287568

    CC-486 and Venetoclax for Acute Myeloid Leukemia

    Not yet reported University of Colorado, Denver 35 participants Est. completion 2029-03 2 sites Stand-alone
    Other conditions: AML
    View official trial listing →
  • Recruiting NCT NCT05305859

    Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

    Not yet reported The First Affiliated Hospital of Xiamen University 30 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
    View official trial listing →
  • Recruiting NCT NCT05365035

    A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

    Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05401097

    IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

    Not yet reported Alice Mims 125 participants Est. completion 2029-06-30 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05404906

    AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 124 participants Est. completion 2030-06 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML) in Remission
    View official trial listing →
  • Recruiting NCT NCT05442216

    Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

    Not yet reported Joshua Zeidner 53 participants Est. completion 2031-07-21 7 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05529069

    Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2027-04-28 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
    View official trial listing →
  • Recruiting NCT NCT05530421

    Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

    Not yet reported University of Miami 33 participants Est. completion 2030-03-26 3 sites Stand-alone
    Other conditions: Relapsed and Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05536349

    Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

    Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2028-04-25 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Recruiting NCT NCT05554406

    Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

    Not yet reported National Cancer Institute (NCI) 335 participants Est. completion 2027-03-31 226 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
    View official trial listing →
  • Recruiting NCT NCT05564390

    MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

    Not yet reported National Cancer Institute (NCI) 2000 participants Est. completion 2029-05-15 355 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
    View official trial listing →
  • Recruiting NCT NCT05566054

    Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

    Not yet reported The First Affiliated Hospital of Soochow University 92 participants Est. completion 2026-09-30 1 site Stand-alone
    Other conditions: Acute Monocytic Leukemia, Newly Diagnosed
    View official trial listing →
  • Recruiting NCT NCT05584761

    Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML

    Not yet reported, Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05587049

    A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

    AbbVie 70 participants Est. completion 2026-11 8 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05657652

    CAV Regimen for R/R Ph- B-ALL

    Not yet reported The First Affiliated Hospital of Soochow University 36 participants Est. completion 2026-10 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05668026

    Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

    Not yet reported, Not yet reported University of Aarhus 18 participants Est. completion 2027-12-01 2 sites Stand-alone
    Other conditions: HIV-1-infection
    View official trial listing →
  • Recruiting NCT NCT05724121

    Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

    National Heart, Lung, and Blood Institute (NHLBI) 135 participants Est. completion 2027-04-08 1 site
    Substance use disorder Other conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Cardiac Arrhythmias, Hematologic Malignancies
    View official trial listing →
  • Recruiting NCT NCT05725200

    Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

    Not yet reported Oslo University Hospital 40 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT05735184

    A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Not yet reported Kura Oncology, Inc. 420 participants Est. completion 2030-04 44 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05736978

    Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

    Not yet reported Shanghai Tong Ren Hospital 58 participants Est. completion 2027-03-15 4 sites Stand-alone
    Other conditions: AML, MRD
    View official trial listing →
  • Recruiting NCT NCT05791409

    Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

    Not yet reported, Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 112 participants Est. completion 2032-12 29 sites Stand-alone
    Other conditions: CLL/SLL
    View official trial listing →
  • Recruiting NCT NCT05807932

    Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

    Not yet reported, Not yet reported Heinrich-Heine University, Duesseldorf 38 participants Est. completion 2029-04-30 6 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05834244

    A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

    Not yet reported M.D. Anderson Cancer Center 32 participants Est. completion 2028-06-30 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05853965

    Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

    Not yet reported, Not yet reported Universitätsklinikum Hamburg-Eppendorf 45 participants Est. completion 2028-12 5 sites Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse
    View official trial listing →
  • Recruiting NCT NCT05870995

    Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

    Not yet reported Shanghai Jiao Tong University School of Medicine 100 participants Est. completion 2026-09-01 3 sites Stand-alone
    Other conditions: Refractory Leukemia
    View official trial listing →
  • Recruiting NCT NCT05904106

    Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

    Not yet reported Technische Universität Dresden 146 participants Est. completion 2030-09 18 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05909293

    Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 100 participants Est. completion 2028-05-30 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05910801

    Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported Academic and Community Cancer Research United 100 participants Est. completion 2030-12-30 2 sites Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05947851

    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    Not yet reported Merck Sharp & Dohme LLC 735 participants Est. completion 2035-07-01 84 sites Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
    View official trial listing →
  • Recruiting NCT NCT05986240

    Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

    Not yet reported Montefiore Medical Center 38 participants Est. completion 2030-03 2 sites Stand-alone
    Other conditions: AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT06014489

    A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

    Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 142 participants Est. completion 2028-12 19 sites Stand-alone
    Other conditions: AML, Adult
    View official trial listing →
  • Recruiting NCT NCT06082934

    Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

    Not yet reported, Not yet reported Xijing Hospital 30 participants Est. completion 2026-11-01 1 site Stand-alone
    Other conditions: Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06115135

    A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

    Not yet reported Oncotherapeutics 39 participants Est. completion 2027-12-31 2 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
    View official trial listing →
  • Recruiting NCT NCT06156579

    Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

    Not yet reported University Hospital Tuebingen 27 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: AML, MDS
    View official trial listing →
  • Recruiting NCT NCT06177067

    Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

    Not yet reported St. Jude Children's Research Hospital 24 participants Est. completion 2027-04 10 sites Stand-alone
    Other conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
    View official trial listing →
  • Recruiting NCT NCT06191978

    A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06192979

    Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

    Not yet reported Jin Lu, MD 41 participants Est. completion 2027-03-31 7 sites
    Other conditions: Amyloidosis; Systemic, AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06220162

    VAC Regimen for AML Patients Who Failed to Response to VA Regimen

    Not yet reported The First Affiliated Hospital of Soochow University 32 participants Est. completion 2026-12-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06237192

    MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

    Not yet reported National Research Center for Hematology, Russia 200 participants Est. completion 2027-09-01 1 site Stand-alone
    Other conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06265545

    Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 458 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: AML, Refractory, Relapsed
    View official trial listing →
  • Recruiting NCT NCT06279572

    Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

    Mayo Clinic 80 participants Est. completion 2027-12-31 3 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06284486

    A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 8 participants Est. completion 2028-12-30 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06301425

    MRD Response-adapted Allo-HSCT for Adverse-risk AML

    Not yet reported Peking University People's Hospital 178 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06329999

    A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

    Not yet reported Ruijin Hospital 78 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06361329

    Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

    Not yet reported First Affiliated Hospital of Zhejiang University 81 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: ETP-ALL
    View official trial listing →
  • Recruiting NCT NCT06372717

    A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

    Not yet reported Apollo Therapeutics Ltd 100 participants Est. completion 2027-05-01 9 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT06387121

    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 53 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06393985

    Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

    Not yet reported The First Affiliated Hospital of Soochow University 30 participants Est. completion 2027-04-25 1 site Stand-alone
    Other conditions: B-cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06394011

    Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

    Not yet reported The First Affiliated Hospital of Soochow University 60 participants Est. completion 2026-12-30 1 site Stand-alone
    Other conditions: Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06397027

    A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2030-12-31 1 site Stand-alone
    Other conditions: Refractory Acute Leukemia, Pediatric Relapsed
    View official trial listing →
  • Recruiting NCT NCT06429449

    Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

    Not yet reported University of Colorado, Denver 30 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06445959

    Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 78 participants Est. completion 2029-06-30 5 sites Stand-alone
    Other conditions: Mutant IDH1 Inhibitor Olutasidenib
    View official trial listing →
  • Recruiting NCT NCT06447090

    VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 30 participants Est. completion 2027-10-31 1 site
    Other conditions: Relapse Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06448013

    A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2030-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06451861

    Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

    Not yet reported Guangdong Provincial People's Hospital 240 participants Est. completion 2027-06-30 13 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06466122

    Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

    Not yet reported Kerry Rogers 30 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06466395

    A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: Refractory Acute Leukemia, Relapsed Acute Leukemia, Undifferentiated Leukemia, Bi-Phenotypic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06471946

    VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

    Not yet reported, Not yet reported Navy General Hospital, Beijing 54 participants Est. completion 2030-09-01 1 site Stand-alone
    Other conditions: Higher-risk Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT06481228

    Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 82 participants Est. completion 2028-06-01 1 site Stand-alone
    Other conditions: Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
    View official trial listing →
  • Recruiting NCT NCT06481241

    Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 77 participants Est. completion 2028-06 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
    View official trial listing →
  • Recruiting NCT NCT06496308

    Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

    Not yet reported Ruijin Hospital 78 participants Est. completion 2027-07-10 1 site
    Other conditions: Mantle Cell Lymphoma (MCL)
    View official trial listing →
  • Recruiting NCT NCT06501196

    A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    Not yet reported BlossomHill Therapeutics 170 participants Est. completion 2027-06 13 sites Stand-alone
    Other conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06504459

    Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

    Not yet reported OHSU Knight Cancer Institute 40 participants Est. completion 2028-05-01 2 sites Stand-alone
    Other conditions: Acute Monocytic Leukemia, Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06511882

    Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 37 participants Est. completion 2028-08 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06520098

    A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Not yet reported VA Office of Research and Development 100 participants Est. completion 2030-12-31 4 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06536959

    VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

    Not yet reported Beijing 302 Hospital 67 participants Est. completion 2027-07-31 1 site Stand-alone
    Other conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
    View official trial listing →
  • Recruiting NCT NCT06557421

    De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

    Not yet reported Institut Paoli-Calmettes 50 participants Est. completion 2028-11-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06558604

    Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

    Not yet reported The Lymphoma Academic Research Organisation 100 participants Est. completion 2032-03 16 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Recruiting NCT NCT06561074

    A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06561880

    The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 66 participants Est. completion 2027-08-31 1 site Stand-alone
    Other conditions: FLT3 Gene Mutation, AML
    View official trial listing →
  • Recruiting NCT NCT06571825

    RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

    Not yet reported He Huang 118 participants Est. completion 2028-02-28 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06580106

    Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

    Wake Forest University Health Sciences 50 participants Est. completion 2030-01 2 sites
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Recruiting NCT NCT06621212

    Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

    Not yet reported First Affiliated Hospital of Zhejiang University 72 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
    View official trial listing →
  • Recruiting NCT NCT06634394

    APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

    Not yet reported Aptevo Therapeutics 39 participants Est. completion 2028-03 7 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT06644183

    Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported Jennifer R. Brown, MD, PhD 64 participants Est. completion 2032-10-01 1 site Stand-alone
    Other conditions: Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia, Relapsed Cancer, Refractory Leukemia
    View official trial listing →
  • Recruiting NCT NCT06649812

    Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 120 participants Est. completion 2028-09-01 113 sites Stand-alone
    Other conditions: High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06651970

    Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

    Not yet reported AstraZeneca 60 participants Est. completion 2032-09-30 23 sites
    Other conditions: Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
    View official trial listing →
  • Recruiting NCT NCT06660368

    BCL2i CLAG-M in R/R Acute Myeloid Leukemia

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 52 participants Est. completion 2027-11 2 sites Stand-alone
    Other conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT06686108

    Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

    Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 59 participants Est. completion 2028-10-30 1 site Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse
    View official trial listing →
  • Recruiting NCT NCT06696183

    Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

    Not yet reported Technische Universität Dresden 60 participants Est. completion 2030-04 1 site Stand-alone
    Other conditions: AML - Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06712121

    Venetoclax and Decitabine in R/R T-ALL

    Not yet reported Seoul National University Hospital 28 participants Est. completion 2028-08-31 3 sites Stand-alone
    Other conditions: T Lymphoblastic Leukemia/Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06737523

    Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

    Not yet reported The First Affiliated Hospital of Xiamen University 30 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Relapse, Refractory AML
    View official trial listing →
  • Recruiting NCT NCT06742463

    VHAG in Treating R/R T-ALL/LBL

    Not yet reported First Affiliated Hospital of Zhejiang University 50 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Acute T Lymphpblastic Leukemia/Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06754267

    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

    Not yet reported First Affiliated Hospital of Zhejiang University 36 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Precursor B-Cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06757855

    Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 29 participants Est. completion 2028-12-01 1 site
    Other conditions: CML,Blast Phase
    View official trial listing →
  • Recruiting NCT NCT06763341

    A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported City of Hope Medical Center 12 participants Est. completion 2027-01-16 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06764238

    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 1800 participants Est. completion 2031-06 27 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
    View official trial listing →
  • Recruiting NCT NCT06778187

    Oral-ATO for TP53-mutated Myeloid Malignancies

    Not yet reported The University of Hong Kong 30 participants Est. completion 2028-02 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, TP53 Gene Mutation, Arsenic Trioxide
    View official trial listing →
  • Recruiting NCT NCT06783790

    Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: AML (Acute Myelogenous Leukemia)
    View official trial listing →
  • Recruiting NCT NCT06810778

    Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

    Not yet reported, Not yet reported Jonsson Comprehensive Cancer Center 12 participants Est. completion 2031-06-01 1 site Stand-alone
    Other conditions: T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
    View official trial listing →
  • Recruiting NCT NCT06852222

    A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

    Not yet reported Janssen Research & Development, LLC 600 participants Est. completion 2029-08-15 266 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Recruiting NCT NCT06863259

    Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

    Not yet reported Children's Hospital Medical Center, Cincinnati 28 participants Est. completion 2029-01-01 1 site Stand-alone
    Other conditions: B-cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06928376

    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

    Not yet reported Chinese PLA General Hospital 160 participants Est. completion 2026-09-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, First Line Therapy
    View official trial listing →
  • Recruiting NCT NCT06958705

    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 79 participants Est. completion 2028-02-01 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Recruiting NCT NCT06990321

    Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

    Not yet reported Yehui Tan 68 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Elderly
    View official trial listing →
  • Recruiting NCT NCT07007052

    Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

    Not yet reported French Innovative Leukemia Organisation 33 participants Est. completion 2031-10-02 34 sites Stand-alone
    Other conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    View official trial listing →
  • Recruiting NCT NCT07007312

    Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

    Not yet reported Kura Oncology, Inc. 1300 participants Est. completion 2031-11 122 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT07007949

    a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

    Not yet reported The First Affiliated Hospital of Soochow University 42 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib
    View official trial listing →
  • Recruiting NCT NCT07014917

    Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

    Not yet reported Zulfa Omer 62 participants Est. completion 2032-06-05 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL Variant
    View official trial listing →
  • Recruiting NCT NCT07023588

    Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

    Not yet reported Yehui Tan 70 participants Est. completion 2029-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT07024706

    Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

    Not yet reported AstraZeneca 80 participants Est. completion 2033-03-23 36 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Recruiting NCT NCT07032727

    Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

    Not yet reported M.D. Anderson Cancer Center 68 participants Est. completion 2029-06-01 2 sites Stand-alone
    Other conditions: Targeted Therapy, IDH1-Mutated Malignancies, Mutations
    View official trial listing →
  • Recruiting NCT NCT07044544

    Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

    Not yet reported University of Alabama at Birmingham 20 participants Est. completion 2027-01 1 site Stand-alone
    Other conditions: Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT07047183

    Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

    Not yet reported Yehui Tan 46 participants Est. completion 2029-06-30 1 site Stand-alone
    Other conditions: Myelodysplastic Neoplasms, Transplantation
    View official trial listing →
  • Recruiting NCT NCT07059156

    Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL

    Not yet reported, Not yet reported Shanxi Bethune Hospital 50 participants Est. completion 2027-07 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Adult
    View official trial listing →
  • Recruiting NCT NCT07060001

    Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

    Not yet reported The Methodist Hospital Research Institute 112 participants Est. completion 2029-12 1 site
    Other conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
    View official trial listing →
  • Recruiting NCT NCT07078591

    Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

    Not yet reported Beijing 302 Hospital 50 participants Est. completion 2031-06 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07117422

    Venetoclax-Decitabine in Untreated Elderly/Unfit AML

    Not yet reported The Second Hospital of Hebei Medical University 39 participants Est. completion 2027-01-30 1 site Stand-alone
    Other conditions: AML, Adult
    View official trial listing →
  • Recruiting NCT NCT07131059

    MRD-positive AML Clinical Study

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 537 participants Est. completion 2028-10-30 1 site Stand-alone
    Other conditions: AML, Adult
    View official trial listing →
  • Recruiting NCT NCT07132684

    Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 240 participants Est. completion 2028-08-30 1 site Stand-alone
    Other conditions: AML, Adult
    View official trial listing →
  • Recruiting NCT NCT07133997

    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

    Not yet reported City of Hope Medical Center 26 participants Est. completion 2028-06-01 1 site Stand-alone
    Other conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT07148180

    A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

    Not yet reported, Not yet reported Jacqueline Garcia, MD 31 participants Est. completion 2030-12-31 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
    View official trial listing →
  • Recruiting NCT NCT07152041

    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 150 participants Est. completion 2030-06 24 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
    View official trial listing →
  • Recruiting NCT NCT07154264

    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

    Not yet reported Dizal Pharmaceuticals 66 participants Est. completion 2030-01 15 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07159620

    Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

    Not yet reported The First Affiliated Hospital of Soochow University 27 participants Est. completion 2030-09-01 1 site Stand-alone
    Other conditions: Adult T-cell Leukemia/Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07172204

    Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

    Not yet reported First Affiliated Hospital of Zhejiang University 25 participants Est. completion 2029-07-31 5 sites Stand-alone
    Other conditions: Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
    View official trial listing →
  • Recruiting NCT NCT07177079

    High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

    Not yet reported Kittika Poonsombudlert 30 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07183878

    Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

    Not yet reported First Affiliated Hospital of Zhejiang University 138 participants Est. completion 2028-08-20 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT07243483

    Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

    Not yet reported Centre Leon Berard 100 participants Est. completion 2029-01-01 5 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07270978

    Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

    Not yet reported University of Virginia 23 participants Est. completion 2031-07 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT07283094

    FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

    Not yet reported Montefiore Medical Center 33 participants Est. completion 2030-02 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Recruiting NCT NCT07304011

    Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

    Not yet reported University of California, Davis 28 participants Est. completion 2029-12-01 2 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07320235

    Imetelstat Combinations in Relapsed AML

    Not yet reported Douglas Tremblay 36 participants Est. completion 2035-06-15 1 site
    Other conditions: Relapsed Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07392242

    A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

    Not yet reported Memorial Sloan Kettering Cancer Center 45 participants Est. completion 2028-01 7 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07425782

    Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

    Not yet reported The First Affiliated Hospital of Soochow University 216 participants Est. completion 2028-11-26 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk, Hematopoietic Stem Cell Transplant (HSCT)
    View official trial listing →
  • Recruiting NCT NCT07451912

    Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 29 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML
    View official trial listing →
  • Recruiting NCT NCT07454226

    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 92 participants Est. completion 2030-03-01 1 site Stand-alone
    Other conditions: Ph-Like, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT07471841

    Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

    Not yet reported Timothy Pardee 25 participants Est. completion 2029-06 1 site
    Other conditions: IDH1 Mutation, Relapsed / Refractory AML
    View official trial listing →
  • Recruiting NCT NCT07478991

    Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

    Not yet reported PETHEMA Foundation 376 participants Est. completion 2030-04 52 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Adult
    View official trial listing →
  • Recruiting NCT NCT07512700

    Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

    Not yet reported Chinese PLA General Hospital 204 participants Est. completion 2029-10-31 3 sites Stand-alone
    Other conditions: Acute Monocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT07581002

    A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

    Not yet reported, Not yet reported AbbVie 660 participants Est. completion 2032-06 36 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07583888

    VABu Conditioning in Elderly AML HSCT

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2027-08-15 1 site Stand-alone
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Recruiting NCT NCT07602088

    A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia

    Janssen Research & Development, LLC 60 participants Est. completion 2029-11-30 1 site
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Recruiting NCT NCT07617285

    Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

    Not yet reported Peking University People's Hospital 27 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: AML, Refractory/Relapse Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07712848

    DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

    Not yet reported The Second Affiliated Hospital of Kunming Medical University 291 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: AML (Acute Myeloid Leukemia)
    View official trial listing →
  • Recruiting NCT NCT07713732

    TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

    Not yet reported Treeline Biosciences, Inc. 120 participants Est. completion 2030-08-29 3 sites Stand-alone
    Other conditions: Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
    View official trial listing →
  • Recruiting NCT NCT07734038

    Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    Not yet reported Kerry Rogers 155 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07743112

    A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported Maxinovel Pty., Ltd. 43 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07774390

    Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL

    European Research Initiative on CLL 323 participants Est. completion 2034-11-20 1 site
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Completed NCT NCT01328626

    A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

    Not yet reported AbbVie 222 participants Est. completion 2020-05-08 10 sites
    Other conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT01594229

    A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

    Not yet reported AbbVie 60 participants Est. completion 2020-07-14 8 sites
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01686555

    A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

    Not yet reported AbbVie (prior sponsor, Abbott) 97 participants Est. completion 2015-06 15 sites
    Other conditions: Lupus Erythematosus
    View official trial listing →
  • Completed NCT NCT01889186

    A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

    Not yet reported AbbVie 158 participants Est. completion 2020-12-15 48 sites
    Other conditions: Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
    View official trial listing →
  • Completed NCT NCT01969669

    A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

    Not yet reported AbbVie 12 participants Est. completion 2014-09 3 sites
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01969695

    An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

    Not yet reported AbbVie 11 participants Est. completion 2019-12-16 3 sites
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02005471

    A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Hoffmann-La Roche 389 participants Est. completion 2022-08-03 111 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02055820

    A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

    Not yet reported, Not yet reported Hoffmann-La Roche 267 participants Est. completion 2019-06-28 52 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Withdrawn NCT NCT02095574

    A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

    Not yet reported AbbVie Est. completion 2015-01
    Other conditions: Relapsed/Refractory Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02141282

    A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

    Not yet reported AbbVie 127 participants Est. completion 2021-12-22 15 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02187861

    A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

    Not yet reported Hoffmann-La Roche 163 participants Est. completion 2018-03-16 71 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02250937

    Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 116 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT02287233

    A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

    Not yet reported, Not yet reported AbbVie 94 participants Est. completion 2021-08-10 9 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia, AML
    View official trial listing →
  • Completed NCT NCT02296918

    Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

    Not yet reported Acerta Pharma BV 69 participants Est. completion 2025-10-22 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT02391480

    A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

    Not yet reported AbbVie 128 participants Est. completion 2019-07-05 10 sites Stand-alone
    Other conditions: Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
    View official trial listing →
  • Completed NCT NCT02419560

    Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

    Not yet reported Craig Portell, MD 37 participants Est. completion 2021-05 4 sites
    Other conditions: Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell
    View official trial listing →
  • Status unknown NCT NCT02471391

    ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

    Not yet reported Peter MacCallum Cancer Centre, Australia 37 participants Est. completion 2025-06 2 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02611323

    A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Hoffmann-La Roche 133 participants Est. completion 2022-08-04 23 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02670044

    A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

    Not yet reported Hoffmann-La Roche 88 participants Est. completion 2020-12-10 17 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Completed NCT NCT02677324

    Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

    Not yet reported Dana-Farber Cancer Institute 33 participants Est. completion 2022-02-07 4 sites
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Active, not recruiting NCT NCT02689440

    Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

    Not yet reported M.D. Anderson Cancer Center 155 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT02717624

    A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

    Not yet reported Acerta Pharma BV 72 participants Est. completion 2027-08-20 15 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma (MCL)
    View official trial listing →
  • Completed NCT NCT02755597

    A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Not yet reported AbbVie 291 participants Est. completion 2022-08-15 97 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02756611

    A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

    Not yet reported AbbVie 258 participants Est. completion 2022-03-11 67 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT02846623

    Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2027-02-28 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02877550

    Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

    Not yet reported Swiss Cancer Institute 25 participants Est. completion 2022-05-04 6 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT02942290

    A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

    Not yet reported AbbVie 134 participants Est. completion 2026-04-15 37 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes (MDS)
    View official trial listing →
  • Completed NCT NCT02950051

    Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

    Not yet reported German CLL Study Group 926 participants Est. completion 2024-02-29 161 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT02951117

    A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

    Not yet reported AbbVie Est. completion 2021-04-28 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02966756

    A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Not yet reported AbbVie 66 participants Est. completion 2030-12 31 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Completed NCT NCT02966782

    A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

    Not yet reported AbbVie 70 participants Est. completion 2023-04-05 23 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes (MDS)
    View official trial listing →
  • Completed NCT NCT02980731

    A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

    Not yet reported AbbVie 210 participants Est. completion 2021-12-29 33 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Completed NCT NCT02987400

    Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

    Not yet reported Arbeitsgemeinschaft medikamentoese Tumortherapie 22 participants Est. completion 2021-10-19 6 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Active, not recruiting NCT NCT02992522

    Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Beth Christian 22 participants Est. completion 2027-04-15 2 sites Stand-alone
    Other conditions: B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT02993523

    A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

    Not yet reported AbbVie 443 participants Est. completion 2026-06-15 172 sites
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT03000257

    A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

    Not yet reported AbbVie 182 participants Est. completion 2022-03-29 26 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Terminated NCT NCT03000660

    Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

    Not yet reported Tufts Medical Center 3 participants Est. completion 2019-10-10 1 site Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT03036904

    Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

    Not yet reported Weill Medical College of Cornell University 31 participants Est. completion 2021-11-11 6 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03063944

    STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 37 participants Est. completion 2024-03-04 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03064867

    Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported, Not yet reported Molly Gallogly 65 participants Est. completion 2023-08-12 3 sites Stand-alone
    Other conditions: Diffuse Large B-cell-lymphoma
    View official trial listing →
  • Completed NCT NCT03069352

    A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

    Not yet reported AbbVie 211 participants Est. completion 2025-08-21 109 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT03113422

    Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

    Not yet reported PrECOG, LLC. 56 participants Est. completion 2023-01-06 10 sites Stand-alone
    Other conditions: Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
    View official trial listing →
  • Available NCT NCT03123029

    Expanded Access to Venetoclax

    AbbVie
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03128879

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

    Not yet reported M.D. Anderson Cancer Center 59 participants Est. completion 2027-05-31 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT03135262

    A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Hoffmann-La Roche 29 participants Est. completion 2020-04-30 21 sites Stand-alone
    Other conditions: Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Terminated NCT NCT03136497

    A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    Not yet reported Hackensack Meridian Health 10 participants Est. completion 2020-11-09 1 site
    Other conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03181126

    A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

    Not yet reported AbbVie 69 participants Est. completion 2020-11-14 15 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma
    View official trial listing →
  • Terminated NCT NCT03217838

    Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

    Not yet reported AstraZeneca 50 participants Est. completion 2021-03-25 11 sites Stand-alone
    Other conditions: Acute Myeloid Leukaemia
    View official trial listing →
  • Status unknown NCT NCT03226301

    A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

    Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 230 participants Est. completion 2026-06-21 49 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission
    View official trial listing →
  • Completed NCT NCT03226418

    Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

    Not yet reported University of Nebraska 75 participants Est. completion 2024-10-01 1 site Stand-alone
    Other conditions: Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03255096

    A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

    Not yet reported Hoffmann-La Roche 39 participants Est. completion 2019-07-03 9 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03276468

    Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

    Not yet reported The Lymphoma Academic Research Organisation 136 participants Est. completion 2022-08-24 25 sites Stand-alone
    Obstructive sleep apnea Other conditions: Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT03295240

    The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

    Not yet reported Memorial Sloan Kettering Cancer Center 10 participants Est. completion 2024-01-22 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma
    View official trial listing →
  • Completed NCT NCT03310190

    Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

    AbbVie 93 participants Est. completion 2022-04-30 13 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03314181

    A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 156 participants Est. completion 2031-05 40 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03319901

    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 82 participants Est. completion 2028-05-30 5 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03336333

    A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

    Not yet reported BeiGene 590 participants Est. completion 2027-10-31 158 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT03343678

    This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

    Not yet reported Boehringer Ingelheim Est. completion 2020-11-25 Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Completed NCT NCT03390296

    OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2022-02-04 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03399539

    Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

    Not yet reported Mayo Clinic 8 participants Est. completion 2024-02-23 3 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, T(11;14)
    View official trial listing →
  • Terminated NCT NCT03404193

    Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 235 participants Est. completion 2026-03-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia
    View official trial listing →
  • Completed NCT NCT03415035

    Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

    AbbVie 269 participants Est. completion 2026-06-17 60 sites
    Other conditions: Cancer - Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03422393

    Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

    Not yet reported Michael Choi 24 participants Est. completion 2028-08 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT03441555

    A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported AbbVie 36 participants Est. completion 2021-01-25 14 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT03455504

    Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 124 participants Est. completion 2026-07-15 22 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03455517

    Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 77 participants Est. completion 2023-05-11 31 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03462719

    A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Not yet reported Janssen Research & Development, LLC 211 participants Est. completion 2029-04-05 88 sites Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Completed NCT NCT03466294

    Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

    Not yet reported University of Colorado, Denver 42 participants Est. completion 2025-12-04 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03467867

    A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

    Not yet reported Georgetown University 25 participants Est. completion 2026-12 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT03484520

    A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported AbbVie 48 participants Est. completion 2022-12-01 13 sites Stand-alone
    Other conditions: Cancer - Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03504644

    Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

    Not yet reported, Not yet reported ECOG-ACRIN Cancer Research Group 40 participants Est. completion 2028-12-31 170 sites Stand-alone
    Other conditions: Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03513562

    Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

    Not yet reported Ohio State University Comprehensive Cancer Center 28 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Ibrutinib Resistance
    View official trial listing →
  • Completed NCT NCT03534180

    Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

    Not yet reported City of Hope Medical Center 12 participants Est. completion 2023-07-26 2 sites Stand-alone
    Other conditions: Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03534323

    Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 55 participants Est. completion 2026-07-01 7 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Richter Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT03539744

    A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

    Not yet reported AbbVie 265 participants Est. completion 2027-11 180 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03567876

    Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

    Not yet reported Fondazione Italiana Linfomi - ETS 141 participants Est. completion 2025-10-15 35 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Completed NCT NCT03573024

    Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

    Not yet reported University of Colorado, Denver 36 participants Est. completion 2026-02-19 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT03584009

    A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

    Not yet reported Hoffmann-La Roche 103 participants Est. completion 2021-05-06 40 sites Stand-alone
    Other conditions: Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • No Longer Available NCT NCT03592576

    Expanded Access to Navitoclax

    AbbVie
    Other conditions: Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT03609593

    Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

    Not yet reported Nicole Lamanna 42 participants Est. completion 2026-01-27 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03625505

    A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported AbbVie 61 participants Est. completion 2021-08-31 11 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Terminated NCT NCT03634228

    Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 16 participants Est. completion 2022-04-03 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT03639324

    Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

    Not yet reported Virginia Commonwealth University Est. completion 2021-10-18 Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, CLL, Relapsed CLL, Refractory Chronic Lymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, SLL, Relapsed Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Suspended NCT NCT03659669

    A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

    AbbVie 272 participants Est. completion 2027-02-28 13 sites
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Status unknown NCT NCT03662724

    Venetoclax Registry

    Hannover Medical School 100 participants Est. completion 2025-11-01 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT03701321

    Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2020-05-28 3 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT03708003

    Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

    Not yet reported Swiss Cancer Institute 30 participants Est. completion 2025-11-30 11 sites Stand-alone
    Other conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03710772

    Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 51 participants Est. completion 2027-03-22 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03713580

    Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

    Not yet reported Case Comprehensive Cancer Center 25 participants Est. completion 2025-11-07 2 sites Stand-alone
    Other conditions: Non-hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03755947

    Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

    Not yet reported Grupo Cooperativo de Hemopatías Malignas 3 participants Est. completion 2021-02-01 1 site Stand-alone
    Other conditions: B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
    View official trial listing →
  • Active, not recruiting NCT NCT03766763

    Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

    Not yet reported French Innovative Leukemia Organisation 82 participants Est. completion 2030-04-24 23 sites Stand-alone
    Other conditions: Chronic Lymphoid Leukemia
    View official trial listing →
  • Terminated NCT NCT03797261

    A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

    Not yet reported AbbVie 9 participants Est. completion 2019-12-30 17 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT03808610

    Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 53 participants Est. completion 2026-05-05 1 site Stand-alone
    Other conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03824483

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

    Not yet reported Memorial Sloan Kettering Cancer Center 230 participants Est. completion 2027-02 8 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
    View official trial listing →
  • Completed NCT NCT03834688

    Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

    Not yet reported PrECOG, LLC. 33 participants Est. completion 2024-07-26 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03836261

    Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

    Not yet reported Acerta Pharma BV 984 participants Est. completion 2027-04-30 169 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03844048

    An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

    Not yet reported AbbVie 165 participants Est. completion 2027-08 56 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03844815

    Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

    Not yet reported University of Chicago 26 participants Est. completion 2027-12-10 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT03856112

    Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2021-12-31 Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
    View official trial listing →
  • Active, not recruiting NCT NCT03862157

    Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2027-01-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis
    View official trial listing →
  • Completed NCT NCT03873857

    A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

    AbbVie 71 participants Est. completion 2022-09-12 20 sites
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Cancer
    View official trial listing →
  • Terminated NCT NCT03886649

    Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

    Not yet reported Swiss Cancer Institute 7 participants Est. completion 2022-03-08 6 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT03922100

    Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

    Not yet reported, Not yet reported Nerviano Medical Sciences 63 participants Est. completion 2024-08-29 11 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
    View official trial listing →
  • Completed NCT NCT03941964

    A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

    Not yet reported AbbVie 60 participants Est. completion 2022-03-14 16 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03946878

    Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 32 participants Est. completion 2028-02-08 1 site Stand-alone
    Other conditions: Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative, Pleomorphic Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, t(11;14)(q13;q32)
    View official trial listing →
  • Completed NCT NCT03955783

    Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

    Not yet reported Sanjay Mohan 78 participants Est. completion 2024-09-01 4 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT03969420

    Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

    Not yet reported Sumitomo Pharma America, Inc. 11 participants Est. completion 2021-05-14 18 sites
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Suspended NCT NCT03969446

    Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

    Not yet reported City of Hope Medical Center 54 participants Est. completion 2027-07-04 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT03984448

    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

    Not yet reported, Not yet reported National Cancer Institute (NCI) 363 participants Est. completion 2028-04-01 634 sites Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03987958

    A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)

    AbbVie 100 participants Est. completion 2027-07 12 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04016805

    Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

    Not yet reported TG Therapeutics, Inc. 41 participants Est. completion 2022-05-22 3 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT04038437

    A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML

    Not yet reported Jazz Pharmaceuticals 35 participants Est. completion 2022-09-24 8 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04070768

    Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

    Not yet reported John Quigley 18 participants Est. completion 2024-02-20 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04128501

    Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

    Not yet reported M.D. Anderson Cancer Center 100 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04146038

    Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

    Not yet reported Rutgers, The State University of New Jersey 5 participants Est. completion 2022-10-25 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04150887

    Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

    Not yet reported OncoVerity, Inc. 61 participants Est. completion 2027-05-15 23 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Active, not recruiting NCT NCT04159779

    A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece

    AbbVie 180 participants Est. completion 2026-06-30 21 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT04160052

    Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 51 participants Est. completion 2026-02-03 1 site Stand-alone
    Other conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
    View official trial listing →
  • Terminated NCT NCT04161885

    A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

    Not yet reported AbbVie 465 participants Est. completion 2025-09-23 165 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Cancer
    View official trial listing →
  • Completed NCT NCT04171791

    A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

    Not yet reported Yale University 4 participants Est. completion 2021-06-22 1 site Stand-alone
    Other conditions: CTCL
    View official trial listing →
  • Terminated NCT NCT04172844

    Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

    Not yet reported Medical College of Wisconsin 16 participants Est. completion 2022-02-27 2 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT04188405

    Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

    Not yet reported M.D. Anderson Cancer Center 20 participants Est. completion 2026-06-02 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    View official trial listing →
  • Active, not recruiting NCT NCT04227847

    A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

    Not yet reported Seagen, a wholly owned subsidiary of Pfizer 170 participants Est. completion 2028-07-03 52 sites Stand-alone
    Other conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT04230564

    Acute Myeloid Leukemia Real World Treatment Patterns

    Pfizer Est. completion 2021-03-31
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Active, not recruiting NCT NCT04263181

    AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

    Washington University School of Medicine 80 participants Est. completion 2027-01-31 1 site
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT04266795

    A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

    Not yet reported Takeda 164 participants Est. completion 2025-10-06 57 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Active, not recruiting NCT NCT04273139

    Ibrutinib + Venetoclax in Untreated WM

    Not yet reported Dana-Farber Cancer Institute 45 participants Est. completion 2028-02-01 2 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, MYD88 Gene Mutation
    View official trial listing →
  • Terminated NCT NCT04274907

    A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

    Not yet reported AbbVie 2 participants Est. completion 2021-02-02 39 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Cancer
    View official trial listing →
  • Terminated NCT NCT04274933

    A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

    Not yet reported AbbVie 4 participants Est. completion 2020-10-08 18 sites Stand-alone
    Other conditions: Breast Cancer, Cancer
    View official trial listing →
  • Suspended NCT NCT04278768

    Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Not yet reported, Not yet reported Curis, Inc. 366 participants Est. completion 2026-04-01 32 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT04282811

    Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

    Gruppo Italiano Malattie EMatologiche dell'Adulto 321 participants Est. completion 2026-10-31 27 sites
    Other conditions: Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
    View official trial listing →
  • Withdrawn NCT NCT04285268

    Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported Rutgers, The State University of New Jersey Est. completion 2024-09-30 1 site Stand-alone
    Other conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
    View official trial listing →
  • Completed NCT NCT04330820

    Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

    Not yet reported, Not yet reported Technische Universität Dresden 55 participants Est. completion 2025-09-24 12 sites Stand-alone
    Other conditions: Relapsed Adult AML, Refractory AML
    View official trial listing →
  • Terminated NCT NCT04336982

    A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

    Not yet reported Celgene 22 participants Est. completion 2024-04-05 14 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Completed NCT NCT04372433

    IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

    Not yet reported Immune-Onc Therapeutics 67 participants Est. completion 2025-01-31 14 sites Stand-alone
    Other conditions: AML With Monocytic Differentiation, CMML
    View official trial listing →
  • Active, not recruiting NCT NCT04401748

    Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

    Not yet reported AbbVie 531 participants Est. completion 2027-07 220 sites Stand-alone
    Other conditions: Myelodysplastic Syndrome (MDS)
    View official trial listing →
  • Terminated NCT NCT04419389

    APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

    Not yet reported, Not yet reported Aprea Therapeutics 1 participants Est. completion 2021-08-24 4 sites Stand-alone
    Other conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT04422210

    A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

    Not yet reported Hoffmann-La Roche 2 participants Est. completion 2020-11-06 5 sites Stand-alone
    Other conditions: Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04424147

    Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML

    Not yet reported Nanfang Hospital, Southern Medical University 96 participants Est. completion 2022-06-30 1 site Stand-alone
    Other conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia, Salvage Treatment, HVA Regimen
    View official trial listing →
  • Terminated NCT NCT04435691

    Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 110 participants Est. completion 2025-03-25 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04447716

    An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

    Not yet reported Thomas Jefferson University 4 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04447768

    The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Memorial Sloan Kettering Cancer Center 100 participants Est. completion 2027-07 8 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Status unknown NCT NCT04454580

    Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

    Ospedale Maggiore Di Trieste 15 participants Est. completion 2020-09-30 1 site
    Other conditions: Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
    View official trial listing →
  • Active, not recruiting NCT NCT04476199

    Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

    Not yet reported Gruppo Italiano Trapianto di Midollo Osseo 100 participants Est. completion 2025-06-30 25 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04487106

    Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2024-01-25 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT04501939

    Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

    Not yet reported University of California, San Diego 5 participants Est. completion 2026-07-22 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT04512105

    Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

    Not yet reported University of California, Irvine 6 participants Est. completion 2025-02-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory
    View official trial listing →
  • Active, not recruiting NCT NCT04560322

    Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

    Not yet reported Massachusetts General Hospital 40 participants Est. completion 2029-03-01 3 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04572763

    Copanlisib Plus Venetoclax in R/R DLBCL

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 48 participants Est. completion 2026-07-29 3 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04599634

    Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

    Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2024-06-20 1 site Stand-alone
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04603001

    Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

    Not yet reported Eli Lilly and Company 260 participants Est. completion 2027-05 37 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
    View official trial listing →
  • Withdrawn NCT NCT04607772

    Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported, Not yet reported Karyopharm Therapeutics Inc Est. completion 2025-12 18 sites Stand-alone
    Other conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04608318

    Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

    Not yet reported German CLL Study Group 897 participants Est. completion 2027-09 181 sites Stand-alone
    Other conditions: Chronic Lymphoid Leukemia
    View official trial listing →
  • Status unknown NCT NCT04613622

    Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

    National Taiwan University Hospital 500 participants Est. completion 2025-12-31 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT04616274

    Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

    National Taiwan University Hospital 500 participants Est. completion 2025-12-31 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04623541

    Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

    Not yet reported, Not yet reported Genmab 194 participants Est. completion 2028-02 81 sites Stand-alone
    Other conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04639362

    CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

    Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 85 participants Est. completion 2028-12-01 27 sites Stand-alone
    Other conditions: CLL
    View official trial listing →
  • Terminated NCT NCT04655261

    Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia

    AbbVie 5 participants Est. completion 2021-11-09 4 sites
    Other conditions: Chronic Lymphocytic Leukemia (CLL)
    View official trial listing →
  • Terminated NCT NCT04659044

    Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported Academic and Community Cancer Research United 3 participants Est. completion 2024-03-29 5 sites Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT04666649

    Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    Not yet reported University of Maryland, Baltimore 27 participants Est. completion 2025-05-23 1 site Stand-alone
    Other conditions: Relapsed or Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04687761

    Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

    Not yet reported, Not yet reported PETHEMA Foundation 113 participants Est. completion 2025-05-30 15 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, De Novo, Age More 60yr
    View official trial listing →
  • Terminated NCT NCT04702425

    VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

    Not yet reported Novartis Pharmaceuticals 37 participants Est. completion 2024-07-23 9 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
    View official trial listing →
  • Active, not recruiting NCT NCT04739813

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 34 participants Est. completion 2031-06-18 1 site Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04746235

    Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 85 participants Est. completion 2028-10-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04748848

    A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

    Not yet reported Celgene 1 participants Est. completion 2022-03-09 17 sites Stand-alone
    Other conditions: Leukemia, Myeloid
    View official trial listing →
  • Status unknown NCT NCT04752527

    Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

    Not yet reported The First Affiliated Hospital of Soochow University 42 participants Est. completion 2022-12 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Adult
    View official trial listing →
  • Status unknown NCT NCT04754035

    Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

    Not yet reported Paolo Ghia 31 participants Est. completion 2025-09-01 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT04755244

    A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

    Not yet reported ALX Oncology Inc. 14 participants Est. completion 2023-08-16 5 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, AML, Adult
    View official trial listing →
  • Active, not recruiting NCT NCT04763928

    Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 101 participants Est. completion 2026-04 33 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04778397

    Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

    Not yet reported Gilead Sciences 258 participants Est. completion 2024-03-25 156 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT04790045

    Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens

    Not yet reported Paolo Ghia 30 participants Est. completion 2026-12-31
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04802590

    Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

    Not yet reported The Lymphoma Academic Research Organisation 210 participants Est. completion 2030-03-02 45 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04809181

    Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

    Not yet reported First Affiliated Hospital of Zhejiang University 95 participants Est. completion 2026-03-19 1 site Stand-alone
    Other conditions: Hematologic Malignancy, Stem Cell Transplant Complications
    View official trial listing →
  • Terminated NCT NCT04812548

    A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

    Not yet reported Novartis Pharmaceuticals 20 participants Est. completion 2023-05-08 10 sites Stand-alone
    Other conditions: Myelodysplastic Syndrome (MDS)
    View official trial listing →
  • Active, not recruiting NCT NCT04817241

    Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

    Not yet reported, Not yet reported National Cancer Institute (NCI) 5 participants Est. completion 2026-11-05 7 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04822766

    A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia

    Not yet reported Assistance Publique - Hôpitaux de Paris 24 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04826523

    Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)

    AbbVie 150 participants Est. completion 2025-10-20 10 sites
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Active, not recruiting NCT NCT04843904

    Safe Accelerated Venetoclax Escalation in CLL

    Not yet reported Dana-Farber Cancer Institute 40 participants Est. completion 2030-06-02 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04847453

    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2028-06-30 16 sites Stand-alone
    Other conditions: Recurrent AL Amyloidosis, Refractory AL Amyloidosis
    View official trial listing →
  • Status unknown NCT NCT04867928

    Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 35 participants Est. completion 2025-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation
    View official trial listing →
  • Active, not recruiting NCT NCT04872790

    Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

    Not yet reported OHSU Knight Cancer Institute 20 participants Est. completion 2027-12-02 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
    View official trial listing →
  • Completed NCT NCT04887857

    A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

    Not yet reported Celgene 6 participants Est. completion 2024-01-08 10 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Status unknown NCT NCT04904237

    Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.

    Not yet reported Shanghai Jiao Tong University School of Medicine 23 participants Est. completion 2024-06-01 3 sites
    Other conditions: Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04905407

    Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

    Not yet reported Syros Pharmaceuticals 66 participants Est. completion 2024-08-12 28 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04939272

    Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported, Not yet reported City of Hope Medical Center 8 participants Est. completion 2027-02-12 1 site Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04968015

    Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission

    Not yet reported French Innovative Leukemia Organisation 134 participants Est. completion 2029-01-31 26 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT04973618

    Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

    Not yet reported Aptevo Therapeutics Est. completion 2027-01
    Other conditions: AML
    View official trial listing →
  • Active, not recruiting NCT NCT04975919

    Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 20 participants Est. completion 2027-05-31 1 site Stand-alone
    Other conditions: Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04981912

    Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

    Not yet reported University of California, San Diego 4 participants Est. completion 2025-07-31 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT04990778

    Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center Est. completion 2023-03-24 1 site Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05001828

    Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

    Not yet reported Polaris Group 38 participants Est. completion 2026-12 3 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Adult
    View official trial listing →
  • Status unknown NCT NCT05005299

    Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

    Not yet reported Melbourne Health 18 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT05025423

    Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 7 participants Est. completion 2025-05-14 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT05048615

    Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 15 participants Est. completion 2023-01-20 1 site Stand-alone
    Other conditions: AML
    View official trial listing →
  • Active, not recruiting NCT NCT05057494

    A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported AstraZeneca 607 participants Est. completion 2029-04-10 37 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT05105841

    Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Not yet reported AbbVie 20 participants Est. completion 2025-10-09 20 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
    View official trial listing →
  • Active, not recruiting NCT NCT05157971

    Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

    Not yet reported City of Hope Medical Center 24 participants Est. completion 2027-04-12 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT05168202

    A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Not yet reported Bristol-Myers Squibb 56 participants Est. completion 2024-07-30 32 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
    View official trial listing →
  • Active, not recruiting NCT NCT05177731

    Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

    Not yet reported Chen Suning 188 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: AML, Adult, Chemotherapy Effect
    View official trial listing →
  • Completed NCT NCT05190549

    CAV Regimen Bridging to HSCT for R/R AL

    Not yet reported The First Affiliated Hospital of Soochow University 30 participants Est. completion 2024-11-17 1 site
    Other conditions: Acute Leukemia, Relapsed, Acute Leukemia Refractory
    View official trial listing →
  • Active, not recruiting NCT NCT05201066

    Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

    Not yet reported Novartis Pharmaceuticals 33 participants Est. completion 2028-02-14 24 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
    View official trial listing →
  • Terminated NCT NCT05209152

    AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

    Not yet reported Amgen 7 participants Est. completion 2023-12-19 1 site Stand-alone
    Other conditions: Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05211336

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

    Not yet reported National Cancer Institute (NCI) 14 participants Est. completion 2029-06-01 1 site Stand-alone
    Other conditions: Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
    View official trial listing →
  • Status unknown NCT NCT05264883

    Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 170 participants Est. completion 2025-02-28 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT05268003

    A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2026-04-21 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Leukemia
    View official trial listing →
  • Terminated NCT NCT05275439

    Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

    Not yet reported Shattuck Labs, Inc. 106 participants Est. completion 2025-02-06 23 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Status unknown NCT NCT05282719

    Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

    Not yet reported The First Affiliated Hospital of Soochow University 33 participants Est. completion 2023-02 1 site Stand-alone
    Other conditions: Myelodysplastic/Myeloproliferative Neoplasms, Adult
    View official trial listing →
  • Terminated NCT NCT05317936

    Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2025-10-06 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05362942

    Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

    Not yet reported Beijing 302 Hospital 52 participants Est. completion 2024-04-30 Stand-alone
    Other conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease
    View official trial listing →
  • Completed NCT NCT05371054

    Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

    Not yet reported, Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2025-12-16 1 site Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
    View official trial listing →
  • Active, not recruiting NCT NCT05379166

    Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

    Not yet reported Uma Borate 33 participants Est. completion 2026-12-15 3 sites Stand-alone
    Other conditions: Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05391750

    Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

    Not yet reported Emory University 7 participants Est. completion 2028-02-12 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT05424562

    A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

    AbbVie 210 participants Est. completion 2026-08-31 20 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05428969

    A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

    Not yet reported, Not yet reported Faron Pharmaceuticals Ltd 181 participants Est. completion 2027-03 10 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
    View official trial listing →
  • Completed NCT NCT05433532

    Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

    Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2024-04-13 1 site Stand-alone
    Other conditions: Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Mixed Phenotype Acute Leukemia
    View official trial listing →
  • Status unknown NCT NCT05448599

    A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

    Not yet reported, Not yet reported Mabwell (Shanghai) Bioscience Co., Ltd. 120 participants Est. completion 2024-10 1 site
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT05451771

    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

    Not yet reported, Not yet reported Columbia University 53 participants Est. completion 2027-09 4 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT05453903

    A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

    Not yet reported Janssen Research & Development, LLC 196 participants Est. completion 2027-06-30 32 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Active, not recruiting NCT NCT05455294

    Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

    Not yet reported Jacqueline Garcia, MD 16 participants Est. completion 2026-12-31 3 sites Stand-alone
    Other conditions: Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
    View official trial listing →
  • Completed NCT NCT05456048

    Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

    Nanfang Hospital, Southern Medical University 231 participants Est. completion 2022-05-31 1 site
    Other conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality, Cytogenetic Abnormality
    View official trial listing →
  • Terminated NCT NCT05464836

    Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

    Not yet reported M.D. Anderson Cancer Center 2 participants Est. completion 2024-08-12 1 site Stand-alone
    Other conditions: Leukemia, Lymphoblastic, Leukemia
    View official trial listing →
  • Completed NCT NCT05471700

    Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

    Not yet reported Zhujiang Hospital 40 participants Est. completion 2023-04-04 1 site Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Withdrawn NCT NCT05486481

    Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

    Not yet reported, Not yet reported Alfred Chung, MD Est. completion 2028-12-31 Stand-alone
    Other conditions: AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
    View official trial listing →
  • Status unknown NCT NCT05522192

    Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

    Not yet reported, Not yet reported Hui Zeng 70 participants Est. completion 2026-05 1 site Stand-alone
    Other conditions: Relapsed or Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT05528354

    Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

    Not yet reported Zhejiang University 58 participants Est. completion 2025-12-31 1 site
    Other conditions: Hematopoietic Stem Cell Transplantation, TP53
    View official trial listing →
  • Status unknown NCT NCT05546060

    Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

    Not yet reported Beijing Friendship Hospital 20 participants Est. completion 2025-10-01 1 site Stand-alone
    Other conditions: Hemophagocytic Lymphohistiocytosis
    View official trial listing →
  • Status unknown NCT NCT05576532

    Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

    Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 30 participants Est. completion 2025-10-10 1 site
    Other conditions: T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia, Safety, Efficacy, Self
    View official trial listing →
  • Completed NCT NCT05594784

    Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 79 participants Est. completion 2025-03-25 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT05628623

    Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

    Not yet reported Eastern Cooperative Oncology Group 184 participants Est. completion 2027-02 Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Active, not recruiting NCT NCT05650723

    Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

    Not yet reported Weill Medical College of Cornell University 50 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Completed NCT NCT05654194

    Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

    Not yet reported The First Affiliated Hospital of Soochow University 60 participants Est. completion 2026-02-28 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT05662956

    A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

    Not yet reported Hematology department of the 920th hospital 114 participants Est. completion 2025-04-30 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05734495

    Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

    Not yet reported Dana-Farber Cancer Institute 46 participants Est. completion 2033-01-25 2 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Withdrawn NCT NCT05740449

    HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

    Not yet reported, Not yet reported Princess Maxima Center for Pediatric Oncology Est. completion 2029-10-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
    View official trial listing →
  • Active, not recruiting NCT NCT05753501

    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    Not yet reported AbbVie 135 participants Est. completion 2031-03 51 sites Stand-alone
    Other conditions: Hematologic Cancer
    View official trial listing →
  • Withdrawn NCT NCT05766514

    Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

    Not yet reported University of Florida Est. completion 2030-12 1 site
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Withdrawn NCT NCT05774886

    Implantable Microdevice for TNBC - Pilot Study

    Not yet reported Dana-Farber Cancer Institute Est. completion 2028-09-01 Stand-alone
    Other conditions: Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer, Early Stage Triple-Negative Breast Carcinoma, Breast Neoplasms, Breast Carcinoma
    View official trial listing →
  • Terminated NCT NCT05799079

    Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

    Not yet reported Sanjay Mohan 1 participants Est. completion 2024-09-20 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT05807347

    Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

    Not yet reported Hematology department of the 920th hospital 42 participants Est. completion 2026-02-01 1 site Stand-alone
    Other conditions: Refractory/Relapse Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT05809167

    Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT

    Not yet reported The First Affiliated Hospital of Soochow University 55 participants Est. completion 2026-01-20 1 site Stand-alone
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT05823714

    Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

    Not yet reported The First Affiliated Hospital of Soochow University 70 participants Est. completion 2026-01-20 1 site Stand-alone
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT05829226

    A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

    Not yet reported PureTech 101 participants Est. completion 2025-12-31 9 sites Stand-alone
    Other conditions: AML, Adult Recurrent, MDS
    View official trial listing →
  • Status unknown NCT NCT05841771

    Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

    Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 78 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Hypomethylating Agent, Venetoclax, Myeloid Malignancy
    View official trial listing →
  • Suspended NCT NCT05861050

    Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

    Not yet reported, Not yet reported City of Hope Medical Center 50 participants Est. completion 2027-02-01 3 sites Stand-alone
    Other conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05863845

    Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

    Not yet reported Ruijin Hospital 52 participants Est. completion 2025-11-30 Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05864742

    Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Peter MacCallum Cancer Centre, Australia 40 participants Est. completion 2029-06-01 3 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma Refractory
    View official trial listing →
  • Completed NCT NCT05909553

    Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

    Not yet reported AbbVie 15 participants Est. completion 2023-09-22 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT05941585

    Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 60 participants Est. completion 2025-01-17 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT05949762

    Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

    Not yet reported, Not yet reported ZePing Zhou 45 participants Est. completion 2024-04-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05963074

    A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

    Not yet reported Janssen Research & Development, LLC 333 participants Est. completion 2029-03-19 74 sites Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT06007911

    Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported Medical College of Wisconsin Est. completion 2027-04 1 site Stand-alone
    Other conditions: Relapsed Adult AML, Refractory AML
    View official trial listing →
  • Completed NCT NCT06030089

    Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

    Not yet reported Centre Hospitalier Universitaire de Nice 20 participants Est. completion 2025-03-03 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06042725

    MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

    Not yet reported Mayo Clinic 16 participants Est. completion 2027-05-29 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06050941

    Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

    Not yet reported First Affiliated Hospital of Zhejiang University 60 participants Est. completion 2027-04-02 Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Suspended NCT NCT06055621

    Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

    Not yet reported Institut Paoli-Calmettes 35 participants Est. completion 2029-01 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06066242

    Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 113 participants Est. completion 2028-05-10 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT06068621

    Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported Chinese PLA General Hospital 200 participants Est. completion 2025-08-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT06070948

    A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

    Not yet reported AbbVie Est. completion 2025-07-28 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Active, not recruiting NCT NCT06073821

    Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

    Not yet reported BeOne Medicines 652 participants Est. completion 2032-12 201 sites
    Other conditions: CLL
    View official trial listing →
  • Status unknown NCT NCT06078306

    CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

    Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2025-09-10 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT06085638

    Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

    Not yet reported, Not yet reported M.D. Anderson Cancer Center Est. completion 2023-10-20 Stand-alone
    Other conditions: Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT06087419

    A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 42 participants Est. completion 2025-12-30 Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT06090786

    Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 225 participants Est. completion 2027-07
    Other conditions: AML, Adult, Minimal Residual Disease
    View official trial listing →
  • Status unknown NCT NCT06105658

    Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

    Not yet reported Anhui Provincial Hospital 20 participants Est. completion 2026-02-01 1 site Stand-alone
    Other conditions: Acute Myelocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT06150040

    Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

    Not yet reported, Not yet reported Centre Leon Berard 1 participants Est. completion 2025-02-18 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia Refractory
    View official trial listing →
  • Status unknown NCT NCT06162325

    Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients

    Peking Union Medical College Hospital 45 participants Est. completion 2025-12-31 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT06200220

    Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

    Poitiers University Hospital 45 participants Est. completion 2025-12-01 1 site
    Other conditions: Waldenstrom's Macroglobulinaemia Refractory
    View official trial listing →
  • Active, not recruiting NCT NCT06232655

    Cladribine Venetoclax in Monocytic AML

    Not yet reported University of Colorado, Denver 10 participants Est. completion 2027-10 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT06263387

    Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

    French Innovative Leukemia Organisation 230 participants Est. completion 2025-03-30 42 sites
    Other conditions: AML, Adult
    View official trial listing →
  • Not yet recruiting NCT NCT06295029

    Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 200 participants Est. completion 2027-12-31
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06311227

    Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

    Not yet reported National Cancer Institute (NCI) 20 participants Est. completion 2027-05-20 21 sites Stand-alone
    Other conditions: Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
    View official trial listing →
  • Not yet recruiting NCT NCT06387420

    A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

    Not yet reported, Not yet reported Akeso 180 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: ACUTE MYELOID LEUKEMIA; AML
    View official trial listing →
  • Terminated NCT NCT06419634

    Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Not yet reported Bristol-Myers Squibb 34 participants Est. completion 2026-08-28 10 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT06429098

    Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

    Not yet reported The First Affiliated Hospital of Soochow University 40 participants Est. completion 2027-12-31 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06445907

    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 17 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT06449482

    Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 6 participants Est. completion 2025-03-30 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Adult
    View official trial listing →
  • Not yet recruiting NCT NCT06470841

    CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

    Not yet reported Navy General Hospital, Beijing 85 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT06508489

    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

    Not yet reported, Not yet reported Sanofi 7 participants Est. completion 2025-08-08 7 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Suspended NCT NCT06514261

    Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

    Not yet reported National Cancer Institute (NCI) 45 participants Est. completion 2027-09-16 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT06516978

    A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 528 participants Est. completion 2029-04-01 Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06522386

    GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2029-02-28 2 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT06532058

    Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported Changzhou Qianhong Bio-pharma Co., Ltd. 53 participants Est. completion 2025-05-10 10 sites Stand-alone
    Other conditions: Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
    View official trial listing →
  • Enrolling by invitation NCT NCT06544109

    Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 98 participants Est. completion 2028-08-01 1 site Stand-alone
    Other conditions: Acute Promyelocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06629818

    Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

    Not yet reported Peking Union Medical College Hospital 36 participants Est. completion 2027-03-14 1 site Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT06651229

    A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Not yet reported Janssen Research & Development, LLC 85 participants Est. completion 2028-02-09 9 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
    View official trial listing →
  • Enrolling by invitation NCT NCT06697327

    Daunorubicin + Cytarabine + Venetoclax in de Novo AML

    Not yet reported Anhui Medical University 94 participants Est. completion 2026-08-01 1 site Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT06744556

    HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 41 participants Est. completion 2028-06-01 1 site Stand-alone
    Other conditions: AML
    View official trial listing →
  • Not yet recruiting NCT NCT06765928

    Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

    Not yet reported Ruijin Hospital 73 participants Est. completion 2028-01-01 1 site Stand-alone
    Other conditions: MDS, AML, Adult
    View official trial listing →
  • Not yet recruiting NCT NCT06841952

    Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia

    Not yet reported The First Affiliated Hospital of Soochow University 158 participants Est. completion 2030-12-15 1 site Stand-alone
    Other conditions: AML, Adult
    View official trial listing →
  • Withdrawn NCT NCT06903702

    A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2027-06 Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Enrolling by invitation NCT NCT07014462

    A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

    Not yet reported University of Vermont 20 participants Est. completion 2029-06 1 site Stand-alone
    Other conditions: AML - Acute Myeloid Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07026942

    Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML

    Not yet reported, Not yet reported Nationwide Children's Hospital 42 participants Est. completion 2038-07-01 1 site Stand-alone
    Other conditions: Relapsed/Refractory AML
    View official trial listing →
  • Not yet recruiting NCT NCT07052422

    VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 160 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Older Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)
    View official trial listing →
  • Not yet recruiting NCT NCT07091006

    Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML

    Not yet reported Ruijin Hospital 44 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Relapse Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT07187505

    Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

    Not yet reported Anhui Medical University 28 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Acute Promyelocytic Leukemia (APL)
    View official trial listing →
  • Active, not recruiting NCT NCT07199855

    Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

    Not yet reported Zhejiang University 24 participants Est. completion 2029-07-01 1 site Stand-alone
    Other conditions: B-Cell Acute Lymphoblastic Leukemia, Adult
    View official trial listing →
  • Completed NCT NCT07236931

    Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells

    Not yet reported Donghua Zhang 103 participants Est. completion 2026-07-15 1 site Stand-alone
    Other conditions: AML (Acute Myeloid Leukemia)
    View official trial listing →
  • Completed NCT NCT07254611

    Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations

    Fondazione IRCCS Policlinico San Matteo di Pavia 15 participants Est. completion 2023-02-15 1 site
    Other conditions: AML (Acute Myelogenous Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07264010

    Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 87 participants Est. completion 2028-12-30 Stand-alone
    Other conditions: Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
    View official trial listing →
  • Active, not recruiting NCT NCT07318662

    Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML

    Guangdong Provincial People's Hospital 224 participants Est. completion 2027-03-30 1 site
    Other conditions: MDS, CMML
    View official trial listing →
  • Not yet recruiting NCT NCT07319793

    Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT

    Not yet reported Peking University People's Hospital 200 participants Est. completion 2028-06-30
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)
    View official trial listing →
  • Active, not recruiting NCT NCT07387471

    Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

    Not yet reported AbbVie 14 participants Est. completion 2028-07 17 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07392814

    Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia

    Not yet reported Nantes University Hospital 12 participants Est. completion 2030-07-10 1 site Stand-alone
    Other conditions: Leukemia Acute Myeloid - AML
    View official trial listing →
  • Not yet recruiting NCT NCT07407660

    Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

    Not yet reported Peking University People's Hospital 250 participants Est. completion 2030-02-01 Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07423104

    A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia

    Not yet reported University of Rochester 24 participants Est. completion 2030-02-01 Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Not yet recruiting NCT NCT07425808

    FLT3-ITD Targeted Therapy in Fit AML Patients

    Not yet reported, Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 230 participants Est. completion 2032-02-01 Stand-alone
    Other conditions: AML (Acute Myeloid Leukemia)
    View official trial listing →
  • Not yet recruiting NCT NCT07486479

    Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

    Not yet reported The First Affiliated Hospital of Soochow University 204 participants Est. completion 2027-12-31 21 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Not yet recruiting NCT NCT07486726

    Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia

    Not yet reported, Not yet reported Shanghai Jiao Tong University School of Medicine 112 participants Est. completion 2028-10 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Not yet recruiting NCT NCT07522801

    A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

    Not yet reported Philippe ROUSSELOT 93 participants Est. completion 2030-03-01 69 sites Stand-alone
    Other conditions: LAL
    View official trial listing →
  • Not yet recruiting NCT NCT07539818

    Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 788 participants Est. completion 2031-04-01 Stand-alone
    Other conditions: AML
    View official trial listing →
  • Active, not recruiting NCT NCT07541755

    PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL

    Not yet reported Fujian Medical University Union Hospital 40 participants Est. completion 2029-01-31 1 site Stand-alone
    Other conditions: Acute T Lymphoblastic Leukemia (T-ALL)
    View official trial listing →
  • Not yet recruiting NCT NCT07572695

    Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40 participants Est. completion 2028-12
    Other conditions: Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, AML, Relapsed/Refractory
    View official trial listing →
  • Not yet recruiting NCT NCT07602322

    LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure

    Not yet reported Ruijin Hospital 60 participants Est. completion 2028-11-01 1 site Stand-alone
    Other conditions: Large B-cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07605949

    Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

    Not yet reported UNC Lineberger Comprehensive Cancer Center 88 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Leukemia Acute Myeloid
    View official trial listing →
  • Not yet recruiting NCT NCT07635485

    VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML

    Not yet reported The First Affiliated Hospital of Soochow University 50 participants Est. completion 2029-08-31 1 site Stand-alone
    Other conditions: Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)
    View official trial listing →
  • Not yet recruiting NCT NCT07643636

    Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

    Not yet reported Dongguan People's Hospital 46 participants Est. completion 2029-06-01 Stand-alone
    Other conditions: AML (Acute Myeloid Leukemia)
    View official trial listing →
  • Not yet recruiting NCT NCT07664839

    Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

    Not yet reported Shen yang 148 participants Est. completion 2032-05-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation
    View official trial listing →
  • Not yet recruiting NCT NCT07690891

    Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

    Not yet reported Medical College of Wisconsin 30 participants Est. completion 2031-09-01 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07691047

    Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax

    Not yet reported Private Hospital of Confluent, France 130 participants Est. completion 2029-09-30 2 sites
    Other conditions: Chronic Lymphoid Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07726576

    Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

    Not yet reported, Not yet reported University Hospital, Bordeaux 41 participants Est. completion 2031-12 3 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Not yet recruiting NCT NCT07738887

    Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

    Not yet reported The Lymphoma Academic Research Organisation 44 participants Est. completion 2032-06-30 29 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07766850

    Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported, Not yet reported Christer C Nilsson 26 participants Est. completion 2034-09 1 site Stand-alone
    Other conditions: R/R AML
    View official trial listing →
  • Completed NCT NCT07773909

    Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy

    Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 24 participants Est. completion 2023-03-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Enrolling by invitation NCT NCT07813390

    Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure

    Not yet reported Guangdong Second Provincial General Hospital 73 participants Est. completion 2028-08-31 1 site
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Not yet recruiting NCT NCT07828535

    Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 30 participants Est. completion 2032-12-31 Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Not yet recruiting NCT NCT07840976

    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 22 participants Est. completion 2030-05-31 1 site Stand-alone
    Other conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
    View official trial listing →
  • Not yet recruiting NCT NCT07862517

    Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    Not yet reported National Cancer Institute (NCI) 122 participants Est. completion 2027-12-31 Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Venetoclax, Venclexta, Venetoclax Oral Tablet, 200 mg, Venetoclax Oral Tablet, 400 mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.